Pemgarda, a monoclonal antibody infusion therapy intended to protect people who are immunocompromised from COVID-19, has been authorized by the U.S. Food and Drug Administration. The prophylactic treatment is for people who may not develop sufficient resistance to COVID-19 after vaccination because they have medical conditions that weaken their immune system.